Scarica l'app Stockscreener
13.24
1.27%
-0.17
Dopo l'orario di chiusura:
13.25
0.010
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.41
Aprire:
$13.67
Volume 24 ore:
421.65K
Relative Volume:
1.04
Capitalizzazione di mercato:
$169.31M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-1.1758
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-1.56%
1M Prestazione:
-12.55%
6M Prestazione:
-53.72%
1 anno Prestazione:
-2.93%
Intervallo 1D:
$13.23
$14.35
Intervallo di 1 settimana:
$13.20
$14.43
Portata 52W:
$13.07
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.24 | 169.31M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Understanding Momentum Shifts in (TNXP) - Stock Traders Daily
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com South Africa
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Benzinga
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS - MarketBeat
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix presents fibromyalgia drug data at Poland conference By Investing.com - Investing.com South Africa
B2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured Conference - TradingView
TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) Approved by FDA for Fibromyalgia—Tonix Pharmaceuticals Presents Positive Phase 3 Data Showing Rapid Pain Relief and Favorable Benefit-Risk Profile - Minichart
Tonix Pharmaceuticals (TNXP) Highlights New Findings on Tonmya a - GuruFocus
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data - TipRanks
Tonix presents fibromyalgia drug data at Poland conference - Investing.com
Tonix Pharmaceuticals presents Phase 3 post hoc data showing rapid, significant pain relief with TONMYA - TradingView
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia - The Manila Times
First new fibromyalgia drug in 15 years shows pain relief by Day 2 - Stock Titan
Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday - MarketBeat
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
New fibromyalgia drug Tonmya cuts pain in 14-week trial - Stock Titan
Is Tonix Pharmaceuticals Holding Corp stock a hidden gem2026 Growth vs Value & High Win Rate Trade Tips - baoquankhu1.vn
Is Tonix Pharmaceuticals Holding Corp. stock safe for conservative investors2026 Sector Review & Real-Time Volume Triggers - Naître et grandir
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development - Sahm
TNXP: Tonix Pharmaceuticals Shares Promising Results from Clinical Studies - GuruFocus
TONMYA fibromyalgia tablet under tongue bypasses first-pass liver metabolism - Stock Titan
Tonix Pharmaceuticals Announces Publication of Clinical - GlobeNewswire
Tonix Pharmaceuticals: Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones - TradingView
Tonix Pharmaceuticals moves to Nasdaq Global Select Market - Investing.com Australia
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - Bitget
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the - GlobeNewswire
Tonix Pharmaceuticals Announces Uplisting From Nasdaq Capital Market to Nasdaq Global Select Market - 富途牛牛
Tonix Pharma Uplists to Nasdaq Global Select Market - TipRanks
Tonix Pharmaceuticals announces uplisting from Nasdaq Capital Market to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals Moves Listing to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals (TNXP) Moves to Nasdaq Global Select Marke - GuruFocus
Tonix Pharmaceuticals approved to transfer listing to Nasdaq Global Select Market - TradingView
Tonix Pharmaceuticals moves to Nasdaq Global Select Market By Investing.com - Investing.com UK
Tonix Pharmaceuticals (NASDAQ: TNXP) uplists to Nasdaq Global Select tier - Stock Titan
Biotech Tonix joins Nasdaq’s top tier, which may boost visibility - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting - Benzinga
Tonix Pharmaceuticals : March 2026 Investor Deck - marketscreener.com
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March - Sahm
TNXP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tonix (TNXP) COO awarded two stock option grants under 2020 plan - Stock Titan
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):